Werewolf Therapeutics, Inc.
HOWL
Rank in Stocks
#22820
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Share Price
$1.01
Last synced: 2026-11-09
Market Cap
$49.09M
Change (1 day)
0.00%
Change (1 year)
-7.34%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Werewolf Therapeutics, Inc. (HOWL)
Category
Healthcare
Operating Margin for Werewolf Therapeutics, Inc. (HOWL)
Operating Margin as of November 2026 TTM: -121.78%
According to Werewolf Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -121.78%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Werewolf Therapeutics, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -121.78% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -3,904.19% | 1,822.39% |
| 2023 | -203.09% | -40.58% |
| 2022 | -341.78% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.32% |
US
|
|
| -149.01% | -98.78% |
US
|
|
| 25.57% | -100.21% |
AU
|
|
| 31.23% | -100.26% |
BE
|
|
| 29.35% | -100.24% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Werewolf Therapeutics, Inc.'s operating margin
What is Werewolf Therapeutics, Inc.'s operating margin?
Werewolf Therapeutics, Inc.'s operating margin is -121.78%, as of Nov 2026.
What was Werewolf Therapeutics, Inc.'s operating margin in 2025?
In 2025, Werewolf Therapeutics, Inc.'s operating margin was 0.00%, compared with -3,904.19% in 2024.
How has Werewolf Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Werewolf Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2024 (-3,904.19%).
How does Werewolf Therapeutics, Inc.'s operating margin compare with similar companies?
Werewolf Therapeutics, Inc.'s operating margin (-121.78%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.